Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Completed 3Withdrawn 2Unknown 1Terminated 1Recruiting 1Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1

Conditions

Leukemia 15Precursor Cell Lymphoblastic Leukemia-Lymphoma 8Lymphoma, Non-Hodgkin 8Lymphoma 8Leukemia, Myeloid, Acute 8Multiple Myeloma 6Myelodysplastic Syndromes 5Lymphoma, Large B-Cell, Diffuse 5Leukemia, Myeloid, Chronic-Phase 5Neuroblastoma 4Hodgkin Disease 4Graft vs Host Disease 4Congenital Abnormalities 4Recurrence 3Neoplasms, Plasma Cell 3Lymphoma, Mantle-Cell 3Lymphoma, Large-Cell, Immunoblastic 3Lymphoma, Follicular 3Leukemia, Myelomonocytic, Juvenile 3Leukemia, Lymphocytic, Chronic, B-Cell 3Burkitt Lymphoma 3Sarcoma 2Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 2Neuroectodermal Tumors, Primitive, Peripheral 2Lymphoma, Large-Cell, Anaplastic 2Lymphoma, Extranodal NK-T-Cell 2Lymphoma, B-Cell, Marginal Zone 2Leukemia, Myelomonocytic, Acute 2Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative 2Leukemia, Myeloid, Accelerated Phase 2

Interventions

Cyclophosphamide 5fludarabine 4N-(2-amino-5-fluorobenzyl)-4-(N-(pyridine-3-acrylyl)aminomethyl)benzamide 3Gemcitabine 3fludarabine phosphate 2endostar protein 2Melphalan 2Etoposide 2Doxorubicin 2Cisplatin 2Alemtuzumab 2thymoglobulin 1spartalizumab 1selinexor 1pembrolizumab 1Vindesine 1Vincristine 1Sensitivity and Specificity 1Rituximab 1Prednisone 1Prednisolone 1Methylprednisolone 1Interleukin-2 1Flavin-Adenine Dinucleotide 1Epirubicin 1Endostatins 1Drug Therapy 1Dexamethasone 1Cytarabine 1Clinical Protocols 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Unknown × Lymphoma, T-Cell × Busulfan × Clear all
NCT05466318 2022-07-25

ChiCGB vs BEAM in High-risk or R/R Lymphomas

Sichuan University

Phase 3 Unknown
306 enrolled
Lymphoid

Lymphoma, T-Cell, Lymphoma, Large B-Cell, Diffuse

Data powered by HemOnc (CC BY 4.0) Colophon âš¡